Posted by Michael Wonder on 03 Sep 2018
Agenda for September 5 TC meeting
3 September 2018 - HAS has posted the agenda for the next scheduled TC meeting.
The Transparency Commission will consider the reimbursement of the following technologies:
- Pembrolizumab (Keytruda)
- Exenatide (Bydureon)
- Cariprazine hydrochloride (Reagila)
- Bictegravir sodium with emtricitabine and tenofovir alafenamide fumarate (Biktarvy)
- Velmanase alfa (Lamzede)
- Insulin degludec (Tresiba)
